Following the 2015 Alzheimer’s Association International Conference (AAIC), we interviewed an Alzheimer’s Disease expert on his opinion of the data presentations and the future of Alzheimer’s Disease treatment.
Number of pages:16
Following the 2015 Alzheimer’s Association International Conference (AAIC), we interviewed an Alzheimer’s Disease expert on his opinion of the data presentations and the future of Alzheimer’s Disease treatment. A BioMedTracker Scientific Analyst was also at the meeting, and we will shortly release a full event-driven, AAIC post-report.
KOL thought the overall tone of the meeting was more positive than prior years with a renewed vigor around amyloid targeted therapy.
Early stage agents that looked promising were NPT-088 (Neurophage) and TRV 101 (Treventis).
Solanezumab had positive data from extension study of EXPEDITION 1 and 2, but the interpretation of the data was a stretch (LLY).
KOL didn’t believe the 6mg dose of aducanumab was all that far off the mark and expects Phase III trial to move forward with doses lower than 10mg to avoid ARIA events (BIIB).
BACE Inhibitor data will not be the definitive story for amyloid targeted compounds (MRK).
5-HT6 targeted therapies have a reasonable shot but not expected to garner much support from physicians and families due to very modest improvements (AXON, Lundbeck).
Enrollment of trials is easier for Nuedexta and pimavanserin since there are no black box warnings in elderly patients as there are for antipsychotics (Otsuka, ACAD).
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.